A comparison of the effects and complications of transforaminal Triamcinolone and Ketorolac in radicular low back pain.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201708157984N27

Enrollment

Registered

2017-09-11

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic low back pain. low back pain

Interventions

Intervention 1: In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 30 mg Ketorolac (Toradol, Zahravi, Iran) was injected in the selected level by a curved blunt tip

Treatment - Drugs

In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 30 mg Ketorolac (Toradol, Zahravi, Iran) was injected in the selected level by a curved blunt tip 10 cm needle (C

In control group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 20 mg Triamcinolone (Triamcinolone acetonide, EXIR, IRAN) was injected in the selected level by a curved blunt tip 10

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 20-70 years; Pain that has not responded to treatment for at least 6 weeks; Evidence of Nerve root involvement as disc bulging and/or foraminal stenosis in CT/MRI; VAS > 4; ASA class I, II; Patients’ Informed consent; Exclusion criteria: Patients with coagulopathy; Infection in injection site as Herpetic diseases; Anatomical and congenital spine deformity as severe scoliosis; Surgical history instrument insertion; Psychological severe disorders; History of harmful reaction to local anesthetic and steroid; Patients with motor deficit or progressive neural defect; Cancer; Neural foramen radiological access difficulty; Substance abuse; HIV; Acute trauma; Cauda Equina syndrome; More than 3 level abnormalities; Absence of radicular pain;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Low back pain. Timepoint: Before injection,two weeks,1,3 and 6 month after intervention. Method of measurement: pain score measured with visual analogue scale in Questionnaire.	—

Secondary

Measure	Time frame
Oswestry Disability Index questionnaire (ODI) and straight leg raising test (SLR), complications. Timepoint: Before injection, two weeks, 1,3 and 6 moth after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farnad Imani

Rasool Akram Medical Center

farnadimani@yahoo.com+98 21 6651 5758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026